Wells Fargo Elevates RAPP with Overweight Rating as Analyst Price Forecasts 91% Upside

In early February 2026, Wells Fargo unveiled a positive coverage initiation on Rapport Therapeutics (RAPP), assigning an Overweight recommendation to the biotech stock. The move signals growing confidence among major financial institutions in the company’s growth trajectory. According to analyst research compiled as of mid-January, the consensus price target for RAPP stands at $53.30 per share, translating to a substantial 91.50% upside from the stock’s then-trading price of $27.83.

The forecasted range displays considerable variation, with targets spanning from $40.40 on the conservative end to an ambitious $84.00 at the bullish extreme. This wide dispersion underscores the diverse views within the analyst community regarding RAPP’s potential. The company’s projected annual non-GAAP earnings remain negative at -3.36 EPS, typical for early-stage therapeutics firms focused on development and regulatory milestones rather than profitability.

Institutional Capital Demonstrates Strong Appetite for RAPP

The fund positioning data reveals accelerating momentum behind RAPP among professional investors. A total of 210 funds and institutional investors currently maintain positions in the stock, marking a net addition of five new institutional players in the latest quarter—a 2.44% increase in the number of stakeholders. More significantly, the average portfolio weight dedicated to RAPP across all institutional holdings surged 35.58%, indicating that existing investors are substantially increasing their commitments rather than merely entering new positions.

Over the past three months, total institutional share ownership expanded by 25.96% to reach 51.351 million shares. The put/call ratio for RAPP stands at 0.15, a deeply bullish indicator suggesting that options market participants heavily favor call options over puts, reflecting optimistic sentiment about near-term price appreciation.

Major Investors Racing to Expand RAPP Holdings

The shareholder composition reveals substantial institutional firepower concentrated in the biotech play. Trv Gp V maintains the largest stake with 7.135 million shares representing 14.97% ownership, though the fund made no adjustments last quarter. Arch Venture follows with 3.729 million shares (7.82% ownership), also unchanged.

More striking are the aggressive positioning shifts among other heavyweight investors. Capital International Investors increased its RAPP stake from 2.603 million to 3.403 million shares—a 23.51% increase—while boosting its portfolio allocation in RAPP by 220.10%. Similarly, Cormorant Asset Management added shares from 2.941 million to 3.193 million (up 7.88%) and escalated its allocation by 162.67%. Goldman Sachs Group demonstrated the most dramatic conviction shift, nearly doubling its position from 1.235 million to 2.422 million shares (+49.01%) and expanding its portfolio allocation by 361.31%.

These synchronized buying patterns across top-tier institutions signal emerging consensus that RAPP presents compelling risk-reward dynamics in the current market environment. The combination of Wells Fargo’s positive coverage, rising price targets, growing institutional ownership, and bullish options positioning collectively paint a picture of institutional confidence building around RAPP as a potential breakout opportunity.